Left ventricular assist devices are potentially attractive in terms of the possible benefits to patients with end-stage heart failure, but the available evidence within the report is of very poor quality and the devices are expensive. Left ventricular assist devices are evolving rapidly and experience with their use is increasing in the UK.
The Committee therefore felt that, although there was some suggestion of potential benefits, particularly from haemodynamic studies, the evidence was not of sufficient quality to reach a decision. The Committee noted a need for high quality evaluative research in this area, with duration and quality of life being primary outcome, and taking into account current UK practice and costs.